Skip to main content

Diagnos Inc.(ADK-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.240
Day High0.250
Open:0.250
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
DIAGNOS Provides an Update on Sales and Regulatory Activities for CARA
GlobeNewswire
DIAGNOS Successfully Completes the Renewal of US-FDA Medical Device Establishment Registration
GlobeNewswire
DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants
GlobeNewswire
DIAGNOS to present at Centurion One Capital 9th Annual Toronto Growth Conference
GlobeNewswire
DIAGNOS and ÉTS Announce $1M+ Federal Investment to Propel Next-Generation Retinal AI Innovation
GlobeNewswire
DIAGNOS Announces the Engagement of IBN
GlobeNewswire
DIAGNOS Advances Regulatory Strategy for CARA in Key Markets: Updates on Health Canada, FDA, and SFDA Progress
GlobeNewswire
DIAGNOS Appoints Dr. Ismail Ben Ayed as Chief Artificial Intelligence (AI) Scientist to Accelerate our Innovation in Healthcare
GlobeNewswire
DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on December 5, 2025
GlobeNewswire
DIAGNOS Strengthens Governance and Leadership with the Appointment of Philippe Couillard as Chairman of the Board of Directors
GlobeNewswire
DIAGNOS Welcomes Dr. Pierre-Luc Charlebois to its Advisory Board
GlobeNewswire
DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on November 9, 2025
Newsfile
DIAGNOS to Present at the Centurion One Capital 3rd Annual Bahamas Summit
GlobeNewswire
DIAGNOS Announces Closing of Private Placement
GlobeNewswire
DIAGNOS Announces Private Placement
GlobeNewswire
DIAGNOS to Extend Stock Warrants Exercise Period
GlobeNewswire
DIAGNOS Announces Extension of Stock Warrants Exercise Period
GlobeNewswire
DIAGNOS Files FDA Pre-Submission for its CARA System: Strategic Entry into the U.S. Optometry Market with Support from ORA LLC
GlobeNewswire
DIAGNOS Welcomes Founder of National Vision Associates, Ed Weiner, to its Advisory Board for the United States
GlobeNewswire
DIAGNOS Welcomes Former White House Economic Adviser Dr. Tomas J. Philipson to its Advisory Board for the US Market
GlobeNewswire
DIAGNOS Announces Amendment to Convertible Debentures
AI-generated - The Globe and Mail
Diagnos: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ADK)
AI-generated - The Globe and Mail
Diagnos: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ADK)
GlobeNewswire
DIAGNOS Provides Additional Information on Amendment to Convertible Debentures
GlobeNewswire
DIAGNOS Provides Update on its Health Canada Medical Device Licence Application
GlobeNewswire
DIAGNOS Opens First US Office in Florida
AI-generated - The Globe and Mail
Diagnos: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ADK)
GlobeNewswire
DIAGNOS Announces Amendment to Convertible Debentures
GlobeNewswire
DIAGNOS to File for FDA Pre-Market Authorization of Its AI-Powered CARA SYSTEM and Engages Ora as Regulatory Specialist
Newsfile
DIAGNOS to Present at Centurion One Capital 8th Annual Toronto Growth Conference
GlobeNewswire
Correction - Diagnos Announces Closing of Private Placement
GlobeNewswire
DIAGNOS Announces Closing of Private Placement

Profile

Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.